Abstract
Several lines of evidence indicate that β-catenin acquires oncogenic activity when its intracellular concentration increases as a result of either mutation in the β-catenin gene itself or inactivation of the adenomatous polyposis coli (APC) gene. In an attempt to elucidate the molecular mechanisms underlying hepatocellular carcinogenesis, we have studied the frequency of β-catenin gene alterations in exon 3, a region known to represent a mutation hot spot, and its inappropriate protein expression by immunohistochemistry in 73 hepatocellular carcinomas (HCCs). The results were correlated with different clinical and pathological data, particularly with the presence or not of an associated cirrhosis. Fourteen (19%) HCCs showed β-catenin gene alterations with missense mutations in nine cases and interstitial deletions in five cases. These genetic alterations were present in both cirrhotic and non-cirrhotic groups. By contrast, we did not find any β-catenin gene alterations in the nine fibromellar carcinomas we examined. Nuclear accumulation of the protein was observed in 18 of them (25%). Remarkably, these included ten of the 14 tumors harboring somatic mutations in the β-catenin gene (P<0.001). Our results indicate that accumulation of β-catenin resulting from genetic mutations is a frequent event in non-fibrolamellar type hepatocellular carcinoma. The close association between increased β-catenin protein stability and mutation indicates that immunohistochemistry may be a powerful method for the detection of the mutated protein in future clinical practice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aberle H, Schwartz H and Kemler H. . 1996 J. Cell. Biochem. 61: 514–523.
Alman BA, Li C, Pajerski ME, Diaz-Cano S and Wolfe HJ. . 1997 Am. J. Pathol. 151: 329–334.
Behrens J, von Kries JP, Khul M, Bruhn L, Wedlich D, Grosschedl R and Birchmeier W. . 1996 Nature 382: 638–642.
Boige V, Laurent-Puig P, Fouchet P, Fléjou F, Monges G, Bedossa P, Bioulac-Sage P, Capron F, Schmitz A, Olschwang S and Thomas G. . 1997 Cancer Res. 57: 1986–1990.
De la Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A and Perret C. . 1998 Proc. Natl. Acad. Sci., USA 95: 8847–8851.
Dejean A, Bougueleret L, Grzeschik KH and Tiollais P. . 1987 Nature 322: 70–72.
Edmondson HA and Steiner PE. . 1954 Cancer 7: 462–503.
Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S and Hirohashi S. . 1998 Cancer Res. 58: 3526–3528.
Greenblatt MS, Bennett WP, Hollstein M and Harris CC. . 1994 Cancer Res. 54: 4855–4878.
Gruner BA, DeNapoli TS, Andrews W, Tomlinson G, Bowman L and Weitman SD. . 1998 J. Pediatr. Hematol. Oncol. 20: 274–278.
He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW. . 1998 Science 281: 1509–1512.
Hirohashi S. . 1998 Am. J. Pathol. 153: 333–339.
Inomata M, Ochiai A, Akimoto S, Kitano S, Hirohashi S. . 1996 Cancer Res. 56: 2213–2217.
Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RNM, Phillips MJ, Portman BG, Poulsen H, Scheuer PJ, Schmid M and Thaler H. . 1995 J. Hepatol. 22: 696–699.
Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T, Ishiguro S, Nakamura Y and Miyoshi Y. . 1998 Cancer Res. 58: 1021–1026.
Kitaeva MN, Grogan L, Williams JP, Dimond E, Nakahara K, Hausner P, DeNobile JW, Soballe PW and Kirsch IR. . 1997 Cancer Res. 57: 4478–4481.
Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D and Pietsch T. . 1999 Cancer Res. 59: 269–273.
Laurent-Puig P, Fléjou JF, Fabre M, Bedossa P, Belghiti J, Gayral F and Franco D. . 1992 Hepatology 16: 1171–1175.
Marchio A, Meddeb M, Pineau P, Danglot G, Tiollais P, Bernheim A and Dejean A. . 1997 Genes Chrom. Cancer 18: 59–65.
Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S, Murata M, Shimano T and Nakamura Y. . 1998 Cancer Res. 58: 2524–2527.
Molenaar M, van de Wetering M, Oosterwegel M, Peterson-Maduro J, Godsave S, Korinek V, Roose J, Destree O and Clevers H. . 1996 Cell 86: 391–399.
Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW. . 1997 Science 275: 1787–1790.
Müller O, Nimmrich I, Finke U, Friedl W and Hoffmann A. . 1998 Genes Chrom. Cancer 22: 37–41.
Murakami Y, Hayashi K, Hirohashi S and Sekiya T. . 1991 Cancer Res. 51: 5520–5525.
Nagai H, Pineau P, Tiollais P, Buendia MA and Dejean A. . 1997 Oncogene 4: 2927–2933.
Nollet F, Berx G, Molemans F and van Roy F. . 1996 Genomics 32: 413–424.
Oda H, Imay Y, Nakatsuru Y, Hata JI and Ishikawa T. . 1996 Cancer Res. 56: 3320–3323.
Okuda K, Nakashima T, Kojiro M, Kondo Y and Wada K. . 1989 Gastroenterology 97: 140–146.
Piao Z, Kim H, Jeon BK, Lee WJ and Park C. . 1997 Cancer 80: 865–872.
Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E and Polakis P. . 1997 Science 275: 1790–1792.
Sparks AB, Morin PJ, Vogelstein B and Kinzler KW. . 1998 Cancer Res. 58: 1130–1134.
Terris B, Fléjou JF, Dubois S, Ruszniewski P, Scoazec JY, Belghiti J, Potet F, Bernades P, Mignon M and Hénin D. . 1996 J. Clin. Pathol. Mol. Pathol. 49: M203–M208.
Trevisani F, D'Intino PE, Caraceni P, Pizzo M, Stefanini GF, Mazzioti A, Grazi GL, Gozzetti G, Gasbarrini G and Bernardi M. . 1995 Cancer 75: 2220–2232.
Voeller HJ, Trucia CI and Gelmann EP. . 1998 Cancer Res. 58: 2520–2523.
Wang J, Chenivesse X, Henglein B and Brechot C. . 1990 Nature 343: 555–557.
Willert K and Nusse R. . 1998 Curr. Opin. Genet. Dev. 8: 95–102.
Zhang YJ, Jiang W, Chen CJ, Lee CS, Kahn SM, Santella RM and Weinstein IB. . 1993 Biochem. Biophys. Res. Comm. 29: 1010–1016.
Zhang X, Xu HJ, Murakami Y, Sachse R, Yashima K, Hirohashi S, Hu SX, Benedict WF and Sekiya T. . 1994 Cancer Res. 54: 4177–4182.
Acknowledgements
This work was supported by a grant from the Association pour la Recherche contre le Cancer.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Terris, B., Pineau, P., Bregeaud, L. et al. Close correlation between β-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene 18, 6583–6588 (1999). https://doi.org/10.1038/sj.onc.1203051
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203051
Keywords
This article is cited by
-
Hepatocellular carcinoma and solid pseudopapillary neoplasm of the pancreas complicating familial adenomatous polyposis: two cases and review of the literature
Familial Cancer (2023)
-
Hepatoblastoma: glutamine depletion hinders cell viability in the embryonal subtype but high GLUL expression is associated with better overall survival
Journal of Cancer Research and Clinical Oncology (2021)
-
Action and function of Wnt/β-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma
Journal of Gastroenterology (2017)
-
Correlation of exon 3 β-catenin mutations with glutamine synthetase staining patterns in hepatocellular adenoma and hepatocellular carcinoma
Modern Pathology (2016)
-
C-terminal-truncated HBV X promotes hepato-oncogenesis through inhibition of tumor-suppressive β-catenin/BAMBI signaling
Experimental & Molecular Medicine (2016)